OIPE VOIES

maye 1635

TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission	U.S. Pater arsons are required to respond to a collection Application Number Filling Date First Named Inventor Art Unit Examiner Name Attorney Docket Number NCLOSURES (Check all tha	Filing Date October 19, 1999 First Named Inventor Besterman et al. Art Unit 1635 Examiner Name Epps, J. Attorney Docket Number MET-015US1			
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s)	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Terminal Disclaimer Request for Refund CD, Number of CD(s) emarks TO Form 1449 opies of 5 references (incl. EP Searce ostcard	After Allowance communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):			
Fi	E OF APPLICANT, ATTORN	EY, OR AGENT			
or Individual name Signature Date 0 2 2 1 0 1 1 1 1 1 1 1 1 1 1 1	4				
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Typed or printed name Mc/i55a	Simpson				
Signature Mulissa	Simpson	Date 3/1/04			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Besterman et al.

Application No.:

09/420,692

Filed:

October 19, 1999

Entitled:

MODULATION OF GENE EXPRESSION BY COMBINATION

THERAPY

Examiner:

J. Epps

Group Art Unit:

1635

Attorney Docket No.: MET-015US1 (1002/016)

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants and their attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration.

Applicants state under 37 C.F.R. §1.97(e)(1) that the publications were cited in two European Search Reports issued in connection with counterparts EP Application No. 02 014 371.5 and EP Application No. 02 014 370.7 not more than three months prior to the filing of this statement. Also enclosed are copies of the European Search Reports for the Examiner's Review.

Applicants further state that identifiers B1-B3 and C1 were previously cited in a Supplemental Information Disclosure Statement from the International Search Report in connection with counterpart PCT Application No. PCT/US99/24278 on May 19, 2000 and therefore copies of the references are not enclosed with this submission.

U.S.S.N. 09/420,692 Supplemental Information Disclosure Statement Page 2

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the Office relevant facts and law regarding the appropriate status of such documents.

This Supplemental Information Disclosure Statement is being filed within three (3) months of the mailing of the European Search Reports and are therefore submitted as both timely and proper. Therefore, no fees are believed to be due.

Respectfully submitted,

Date:

2/27/04

Wayne A. Keown Reg. No. 33,923

Keown & Associates 500 West Cummings Park Suite 2900 Woburn, MA 01801 781-938-1805 (Telephone) 781-938-4777 (Facsimile)

OLD E VC,			
0 3 200h 351	•		SH
WAT Subt Form PTO-1449		Docket Number	Applica

A5

MAR 0 3 2004	Y OFFICE	i				SHEET	_1_OF_1_
Subt. Form PT	0-1449			Docket Number		Application I	Number
SUPP	LEMENIA	L INFORMATI		MET-015US1		09/420,6	392
DISCLO	SURE IN	AN APPLICAT	TION		Applic	cant	
/I le	o coveral ch	eats if nacessary	,		Besterma	an et al.	
(Use several sheets if necessary)			Filing Date		Group Art Unit		
			10/19/99		1635		
		U.	S. PATE	NT DOCUMENTS			
EXAMINER INITIAL	IDENTIFIER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						

FOREIGN PATENT DOCUMENTS

EXAMINER	IDENTIFIER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANS	TRANSLATION	
INITIAL		NUMBER					YES	NO	
	B1	WO 97 32604 A	09/1997	PCT					
	B2	WO 97 32589 A	09/1997	PCT					
	B3	WO 94 08625 A	04/1994	PCT					
	B4	WO 97 35990 A	10/1997	PCT					
	B5	WO 99 15648 A	04/1999	PCT					

OTHER DOCUMENTS (including Author Title Date Pertinent Pages Ftc.)

	ОІП	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	IDENTIFIER	
	C1	Ju et al., "Increased Drug Sensitivity of Tumor Cells by manipulation of Cell Cycle Control Genes", Thesis Univ. So. California, pp. 100-130, 1996.
	C2	Amer. Assoc. for Cancer Res.: "Proceedings of the 89th Annual Meeting of the Am. Assoc. for Cancer Res., New Orleans, 39:416 XP002094749, 1998.
	C3	European Search Report in connection with EP Application No. 02 014 371.5.
	C4	European Search Report in connection with EP Application No. 02 014 370.7.
·		
	<u> </u>	
EXAMINER:	<u> </u>	DATE CONSIDERED:

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy with next communication to Applicant.